Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH Conference
March 05 2014 - 4:02PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will webcast its
corporate presentation at the 26th Annual ROTH Conference on
Wednesday March 12th, 2014 at 12:30 pm Pacific.
The presentation will be webcast live and may be accessed from
the Event Calendar page of Sucampo's website at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar.
Presentation slides will be available via the webcast links. A
replay of the webcast will also be available on the Company's
website for several days after the live event. To ensure a timely
connection, it is recommended that users register at least 15
minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical
company focused on innovative research, discovery, development and
commercialization of proprietary drugs based on prostones.
Discovered by the company's scientific founder, prostones are
naturally occurring fatty acid metabolites with unique
physiological activities. Sucampo has two marketed products –
AMITIZA® and RESCULA® – and a pipeline of prostone-based product
candidates in clinical development. A global company, Sucampo is
headquartered in Bethesda, Maryland, and has operations in Japan,
the United Kingdom and Switzerland. For more information, please
visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG. RESCULA is a registered trademark of
R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; Sucampo's ability to accurately predict
future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products;
the risk of new and changing regulation and health policies in the
US and internationally and the exposure to litigation and/or
regulatory actions. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected.
Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 8-K and 10-K, which the Company
incorporates by reference.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter LinkedIn
CONTACT: Silvia Taylor
Senior Vice President, Investor Relations and
Corporate Communications
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Jul 2023 to Jul 2024